Incidence of seroconversion and sero-reversion in patients with multiple sclerosis (MS) who had been treated with natalizumab: A systematic review and meta-analysis

Azimi, Amirreza; Hanaei, Sara; Sahraian, Mohammad Ali; Mohammadifar, Mehdi; Ramagopalan, Sreeram; Ghajarzadeh, Mahsa

doi:10.1016/j.jocn.2019.08.103

Cited by 6 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the results of our study, the JCVAb status changed from positive to negative in 4 patients (1.9%) during the period of observation up to 48 (±3) months and was in line with other studies [19]. In the systematic review and meta-analysis, the incidence of seroreversion was reported between 1 and 11% [6]. In the same study, the pooled estimate of seroreversion incidence rate was 5%, meaning that in 50 per 1,000 MS cases who were treated with NAT, anti-JCV antibody status changed from positive to negative.…”

Section: Color Version Available Onlinesupporting

confidence: 91%

“…The pooled estimate of seroconversion incidence was 19%, which means that in 190 per 1,000 MS cases who had been treated with NAT, anti-JCV antibody status had changed from negative to positive. Subgroup analysis by considering the country of the origin showed that the pooled incidence of seroconversion incidence during the studies was 6% in Asian countries and 21% in European/American countries [6].…”

Section: Discussionmentioning

confidence: 99%

“…But little is known about the true risk of PML among negative for JCVAb patients, given that the JCVAb assay has an estimated analytical false-negative rate of 3% [4]. It is unquestionable that MS patients who are JCVAb seronegative have a lower risk of developing PML, but they can become seropositive during treatment with NAT [5, 6]. In Poland, according to the National Health Fund (NFZ) drug program guidance, only patients with negative JCVAb test have been able to start treatment with NAT.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis

Kapica-Topczewska

Collin²,

Tarasiuk

et al. 2020

Eur Neurol

View full text Add to dashboard Cite

Introduction: Presence of anti-JC-virus antibodies (JCVAbs) is associated with the increased risk of natalizumab (NAT)-related progressive multifocal leukoencephalopathy (PML). Little is known about seroconversion rate and time to seroconversion in relapsing-remitting multiple sclerosis (RRMS) patients treated with NAT in Poland. The aim of the study was to assess the true risk of PML, seroconversion rate, and time to seroconversion in all JCVAb-negative RRMS patients treated with NAT in Poland. Methods: Demographic and clinical data of all Polish RRMS patients treated with NAT reimbursed by National Health Fund (NFZ) were prospectively collected in electronic files using the Therapeutic Programme Monitoring System provided by NFZ. The assessment of JCVAb presence (without collection of JCVAb index value) in serum (Unilabs, STRATIFY JCV: anti-JCV antibody ELISA) was done at the beginning of therapy and then repeated every 6 months. The maximum follow-up time was 4 years. In Poland, since 2013, according to the NFZ drug program guidance, only patients with negative JCVAb test have started treatment with NAT. Results: In all Polish multiple sclerosis centers, 210 negative JCVAb RRMS patients with at least 9 (±3) months of observation (146 females, 64 males, and the median age at baseline: 33 years) were included in the study. During the follow-up period, JCVAb status changed from negative to positive in 34 patients (16.2%). For half of the patients, the seroconversion was diagnosed 1 year after starting NAT treatment. In 4 patients (1.9%) during follow-up, JCVAb status changed again from positive to negative. In Poland, before establishment of NFZ drug program, 4 cases of PML in patients treated with NAT in clinical trials were diagnosed. In the NFZ drug program, since 2013, no patient treated with NAT has been diagnosed with PML. Conclusions: NAT therapy in JCV-seronegative RRMS patients is safe and results in the absence of PML cases. In Poland, JCV seroconversion rate is similar to that observed in other European countries.

show abstract

Section: Color Version Available Onlinesupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis

Kapica-Topczewska

Collin²,

Tarasiuk

et al. 2020

Eur Neurol

View full text Add to dashboard Cite

show abstract

“…The issue is even more prominent for patients who receive immunomodulatory or immunosuppressive agents, like for MS patients. MS patients use diseasemodifying therapies (DMTs) to control relapses and to decrease the progression of the disease (Azimi et al, 2019;Azimi et al, 2020), which predisposes them to the increased risk of infections (Wijnands et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran

Sahraian

Gheini

Rezaeimanesh

et al. 2020

Multiple Sclerosis and Related Disorders

Self Cite

View full text Add to dashboard Cite

“…Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system, with a higher prevalence in women. [ 1 2 ] It has a wide range of negative consequences on personal, social, occupational, and marital aspects of life. [ 3 ] MS can present with a wide range of signs and symptoms based on the location of the lesions and other factors such as disease duration.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of seizure/epilepsy in patients with multiple sclerosis: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Incidence of seroconversion and sero-reversion in patients with multiple sclerosis (MS) who had been treated with natalizumab: A systematic review and meta-analysis

Cited by 6 publications

References 34 publications

John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis

John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis

Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran

Prevalence of seizure/epilepsy in patients with multiple sclerosis: A systematic review and meta-analysis

Contact Info

Product

Resources

About